Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 in Active Noninfectious Intermediate, Posterior, or Panuveitis
NCT05953688Phase 2Terminated
- Sponsor
- Alumis Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of envudeucitinib in non-infectious intermediate uveitis, non-infectious posterior uveitis (NIPU) and non-infectious panuveitis (NIU) (2 arms), sponsored by Alumis Inc. Primary endpoint: Proportion of patients failing treatment by Week 24. Started Jun 2023; status: terminated.
02
Drugs
envudeucitinib
03
Conditions
non-infectious intermediate uveitisnon-infectious posterior uveitis (NIPU)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT05953688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953688.